Thermo Fisher Scientific Q3 FY2026 results
$700.22+0.11%
Thermo Fisher Scientific reported revenue of $12.1 billion, up 9.1% from a year earlier, net income of $1.72 billion and diluted earnings per share of $4.64 against $4.27 for the third quarter of fiscal 2026 (the three months to 26 Sep 2026).
From its quarterly report, the results first announced on 21 Oct 2026. Compiled and checked by AapWire.
Q3 FY2026 against Q3 FY2025
Three months to 26 Sep 2026, against the three months to 27 Sep 2025. Amounts in USD.
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $12.14B | $11.12B | +9.1% |
| Gross profit | $5.13B | $4.58B | +12.0% |
| Gross margin | 42.3% | 41.2% | +1.1 pts |
| Operating income | $2.26B | $1.94B | +16.6% |
| Operating margin | 18.6% | 17.5% | +1.2 pts |
| Net income | $1.72B | $1.62B | +6.5% |
| Diluted EPS | $4.64 | $4.27 | +8.7% |
| Operating cash flow | $2.55B | $2.24B | +13.9% |
| Capital expenditure | $437.0M | $404.0M | +8.2% |
| Free cash flow | $2.11B | $1.83B | +15.1% |
Operating KPIs for the quarter
| KPI | Q3 FY2026 | Change on a year |
|---|---|---|
| Organic revenue (change on a year) | 6% | up 3.0 points |
| Remaining performance obligations | $29.9B | up 12.9% |
| Product revenues | $6.8B | up 4.1% |
| Service revenues | $5.4B | up 16.2% |
| Consumables revenue | $4.9B | up 4.1% |
| Instruments revenue | $1.9B | up 4.0% |
| Clinical research revenue | $2.4B | up 21.1% |
| Research and safety market channel revenue | $2.0B | up 9.1% |
| Pharma services revenue | $2.0B | up 17.8% |
| Biosciences revenue | $1.0B | up 0.2% |
| BioProduction revenue | $896.0M | up 9.7% |
| Chromatography and mass spectrometry revenue | $859.0M | up 2.1% |
| Electron microscopy revenue | $827.0M | up 13.0% |
| Genetic sciences revenue | $702.0M | down 2.5% |
| Laboratory products revenue | $603.0M | up 1.5% |
| Healthcare market channel revenue | $454.0M | up 2.3% |
| Chemical analysis revenue | $316.0M | down 1.2% |
| Clinical diagnostics revenue | $269.0M | down 4.9% |
| ImmunoDiagnostics revenue | $232.0M | up 0.9% |
| Transplant diagnostics revenue | $131.0M | up 4.8% |
Earlier quarters
| Quarter | Period end | Revenue | Change on a year | Diluted EPS |
|---|---|---|---|---|
| Q3 FY2026 | 26 Sep 2026 | $12.14B | +9.1% | $4.64 |
| Q2 FY2026 | 27 Jun 2026 | $11.99B | +10.5% | $4.68 |
| Q1 FY2026 | 28 Mar 2026 | $11.01B | +6.2% | $4.43 |
| Q4 FY2025 | 31 Dec 2025 | $12.21B | +7.2% | $5.21 |
| Q3 FY2025 | 27 Sep 2025 | $11.12B | +4.9% | $4.27 |
| Q2 FY2025 | 28 Jun 2025 | $10.86B | +3.0% | $4.28 |
| Q1 FY2025 | 29 Mar 2025 | $10.36B | +0.2% | $3.98 |
| Q4 FY2024 | 31 Dec 2024 | $11.39B | +4.7% | $4.78 |
More on Thermo Fisher Scientific: financial statements · revenue · earnings per share
TMO's results, as they are filed.
Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.